phrykt

Fate Therapeutics Inc (FATE): who owns it and who trades it

As of Nov 16, 2026, FATE insiders reported 7 open-market sales worth $336K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Bahram Valamehr (CEO), with $168K. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling FATE Therapeutics

From the latest filings

Overall: more selling than buying. Insiders and famous investors mostly sold. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns FATE

156 funds and institutions reported FATE shares worth $195M at the end of Q2 2026, about 62% of the company. The largest holder is Redmile Group, LLC with 11.0%.

Funds and institutions (13F) 62%Everyone else 38%

10 largest owners, by share of the company

Redmile Group, LLC11.0%
BlackRock, Inc.6.3%
Vanguard Portfolio Management LLC3.9%
Vanguard Capital Management LLC3.8%
Acadian Asset Management LLC3.7%
AQR Capital Management LLC3.3%
Two Sigma Investments, LP3.1%
Johnson & Johnson2.9%
Renaissance Technologies LLC2.6%
Millennium Management LLC2.1%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Redmile Group, LLC12.87M11.04%$34.8MNo change
BlackRock, Inc.7.30M6.26%$19.7M-28%
Vanguard Portfolio Management LLC4.55M3.90%$12.3M+10%
Vanguard Capital Management LLC4.45M3.81%$12M+6%
Acadian Asset Management LLC4.35M3.73%$11.7M+6%
AQR Capital Management LLC3.84M3.29%$10.4M+28%
Two Sigma Investments, LP3.59M3.08%$9.7M+4%
Johnson & Johnson3.38M2.90%$9.1MNo change
Renaissance Technologies LLC2.98M2.56%$8.1M+0%
Millennium Management LLC2.43M2.09%$6.6M–
Goldman Sachs Group Inc2.05M1.76%$5.5M+54%
Geode Capital Management, LLC1.32M1.13%$3.6M-49%
T. Rowe Price Investment Management, Inc.1.08M0.93%$2.9M–
Jane Street Group, LLC1.03M0.88%$2.8M+59%
Citadel Advisors LLC993,3080.85%$2.7M+5%
Bruce & Co., Inc.989,1880.85%$2.7M+25%
Morgan Stanley694,5800.60%$1.9M-10%
Vanguard Fiduciary Trust Co640,4280.55%$1.7M-2%
Charles Schwab Investment Management Inc610,9490.52%$1.6M-19%
Sixth Street Partners Management Company, L.P.610,9490.52%$1.6M–

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, FATE insiders reported $0 of open-market purchases and $336K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$336K
7 trades, 3 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Nov 3, 2026
Filed Nov 4, 2026

Purchases and sales by month

$204K$204KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 3, 2026Kamal AdawiCFOSale6,582$2.05$13.5KForm 4
Aug 4, 2026Cindy TahlSee RemarksSale38,800$2.46$95.4KForm 4
Aug 4, 2026Bahram ValamehrCEOSale43,947$2.46$108KForm 4
May 20, 2026Cindy TahlSee RemarksSale25,590$1.88$48.1KForm 4
May 20, 2026Bahram ValamehrCEOSale28,946$1.88$54.4KForm 4
Jan 9, 2026Cindy TahlSee RemarksSale10,589$1.06$11.2KForm 4
Jan 9, 2026Bahram ValamehrCEOSale5,190$1.07$5.6KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Bahram ValamehrPresident and CEO, Director–$168KAug 4, 2026
Cindy TahlSee Remarks–$155KAug 4, 2026
Kamal AdawiChief Financial Officer–$13.5KNov 3, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

FATE short interest

Moderate short interest. 8.2% of FATE shares are sold short: about 1 share in 12. Over the last 12 reports the number of shares short went up 3%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 9.97M FATE shares were sold short, 8.2% of the shares outstanding, down 6.1% from the report before. At the average daily volume of 1.20M shares, buying them all back would take about 8.3 trading days (days to cover).

Shares short, % of all shares

8.20%May 15Oct 309.74%

Days to cover

8.3May 15Oct 3011.9

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20269.97M8.20%-6%1.20M8.3
Oct 15, 202610.62M8.86%-1%1.22M8.7
Sep 30, 202610.76M8.98%+15%2.04M5.3
Sep 15, 20269.39M7.83%+3%893,76910.5
Aug 31, 20269.11M7.60%+7%1.46M6.2
Aug 14, 20268.51M7.10%+11%2.59M3.3
Jul 31, 20267.68M6.59%+5%1.68M4.6
Jul 15, 20267.32M6.28%-2%3.69M2.0
Jun 30, 20267.43M6.38%-31%6.08M1.2
Jun 15, 202610.82M9.28%+1%3.62M3.0
May 29, 202610.70M9.18%+10%5.18M2.1
May 15, 20269.73M8.35%-5%4.91M2.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

FATE Therapeutics company events

FATE Therapeutics filed 8 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026AgreementFate Therapeutics, Inc. entered into a Sales Agreement with Leerink Partners LLC, with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.001 per share, having an aggregate… Filing
  2. Nov 5, 2026ResultsReleased financial results. Filing
  3. Sep 28, 2026AnnouncementThe California Institute for Regenerative Medicine awarded Fate Therapeutics, Inc. a $15 million grant to support the Company’s Phase 2 RECLAIM-LN clinical trial of FT819. Filing
  4. Aug 13, 2026ResultsReleased financial results. Filing
  5. Jun 15, 2026LeadershipAs described below in Item 5.07 of this Current Report on Form 8-K, on June 12, 2026, the stockholders of Fate Therapeutics, Inc. approved a third amendment and restatement of the Company’s 2022 Stock Option and Incentive Plan (as so amended and restated, the “2022 A&R Plan”) to increase the… Filing
  6. Jun 4, 2026AnnouncementFate Therapeutics, Inc. updated its corporate presentation for use in meetings and at conferences, including at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress. Filing
  7. May 13, 2026ResultsReleased financial results. Filing
  8. Feb 26, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

FATE Therapeutics financials

Famous investors that hold FATE

4 of the 50 well-known investors we track reported holding FATE in their latest 13F filing. The largest position is Jim Simons's, worth $5.6M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 20262.37M$5.6M0.0%-20%
Israel Englander · Millennium ManagementQ3 20262.17M$5.1M0.0%-11%
Ken Griffin · Citadel AdvisorsQ3 2026846,920$2M0.0%-15%
Steve Cohen · Point72 Asset ManagementQ3 2026209,501$497K0.0%-53%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named FATE in the last 120 days.

FiledHolderFormStake
Nov 9, 2026Redmile Group, LLC13D/A15.0%
Nov 9, 2026Redmile Group, LLC13D/A15.0%

Questions about Fate Therapeutics Inc (FATE) stock

Who owns the most FATE stock?

The largest reported owner of Fate Therapeutics Inc (FATE) is Redmile Group, LLC, with 11.0% of the company. In total, 156 funds and institutions reported holding FATE at the end of Q2 2026, together about 62% of the shares. See the largest owners.

Are FATE insiders buying or selling?

In the last 12 months, FATE insiders reported no open-market purchases and 7 sales worth $336K. The latest trade was on Nov 3, 2026. See every trade.

What is the short interest in FATE?

As of Oct 30, 2026, 9.97M FATE shares were sold short, 8.2% of the shares outstanding, down 6.1% from the report before. At the average daily volume of 1.20M shares, buying them all back would take about 8.3 trading days (days to cover). See the history.

Which famous investors hold FATE?

4 of the 50 well-known investors we track reported FATE in their latest 13F filing, including Jim Simons, Israel Englander, Ken Griffin. The largest position is worth $5.6M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.